Skip to main content
SpringerLink
Log in

Drug Treatment of Chemotherapy-Induced Delayed Emesis

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Chemotherapy-induced emesis has a major adverse impact on patients undergoing therapy for various malignancies, and this has led to considerable research in this field. Most investigative efforts have concentrated on the acute phase of emesis that occurs within the first 24 hours after chemotherapy, and significant strides forward have been made with this problem. Better control of acute emesis with newer agents such as the serotonin 5-HT3 receptor antagonists has focused increasing attention on a second phase of nausea and vomiting, known as delayed emesis, which occurs more than 24 hours after chemotherapy. This delayed phase is often not as well controlled with the antiemetics that have proven effective in acute emesis, and contributes to the distress associated with emetogenic chemotherapy.

Most of the available data on delayed emesis are based on studies with cis-platin-based regimens, with much less understanding of delayed nausea and vomiting induced by non-cisplatin-based chemotherapy. Nevertheless, it is evident that the patterns of delayed emesis associated with cisplatin and non-cisplatin chemotherapy have distinct differences.

The control of delayed emesis, especially following cisplatin, remains a therapeutic challenge. Contributing to the lack of progress has been the absence of an experimental model to help in elucidating the pathophysiology of delayed emesis and in the evaluation of new therapeutic approaches. The combination of metoclopramide and dexamethasone, although superior to placebo in randomised trials, provides only moderate control of delayed emesis following high-dose cisplatin. The 5-HT3 receptor antagonists that are effective in the prevention of acute emesis with cisplatin have failed to make a major impact on the delayed phase. When combined with dexamethasone, these agents provide no additional benefit to that achieved using dexamethasone alone or dexamethasone combined with metoclopramide. With non-cisplatin chemotherapy, corticosteroids and 5-HT3 receptor antagonists are the most useful agents.

Efforts are ongoing to identify more effective treatments for delayed emesis. One novel approach involves the blockade of substance P binding to neurokinin-1 (NK1) receptors. This article reviews what is currently known about chemotherapy-induced delayed emesis, with a focus on treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med 1993; 329: 1790–6

    Article  PubMed  CAS  Google Scholar 

  2. Hesketh PJ. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists. Support Care Cancer 1994; 2: 286–92

    Article  PubMed  CAS  Google Scholar 

  3. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3(10): 1379–84

    PubMed  CAS  Google Scholar 

  4. Martin M, Diaz-Rubio E, Sanchez A, et al. The natural course of carboplatin-induced emesis. Acta Oncologica 1990; 29: 593–5

    Article  PubMed  CAS  Google Scholar 

  5. Fetting JH, Grochow LB, Folstein MF, et al. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rev 1982; 66: 1487–93

    CAS  Google Scholar 

  6. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 305: 905–9

    Article  PubMed  CAS  Google Scholar 

  7. Martin M. Pattern of emesis with various chemotherapeutic agents. Support Care Cancer. In press

  8. Kris MG, Gralla RH, Tyson LB, et al. Controlling delayed vomiting: double-blind randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108–14

    PubMed  CAS  Google Scholar 

  9. Gandara DR, Harvey WH, Monaghan GG, et al. The delayed emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol 1992 Aug; 19 (4 Suppl. 10): 67–71

    PubMed  CAS  Google Scholar 

  10. Passalacqua R, Cocconi G, Bella M, et al. Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH). Ann Oncol 1992; 3: 481–5

    PubMed  CAS  Google Scholar 

  11. Roila F, Boschetti E, Tonato M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol Cancer Clin Trials 1991; 14(3): 238–42

    CAS  Google Scholar 

  12. Shinkai T, Saijo N, Eguchi K, et al. Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial. Jpn J Clin Oncol 1989; 19(1): 40–4

    PubMed  CAS  Google Scholar 

  13. Florczyk AP, Schurig JE, Bradner WT, et al. Cisplatin-induced emesis in the ferret: a new animal model. Cancer Treat Rev 1982; 66: 187–9

    CAS  Google Scholar 

  14. Neuwelt EA, Glasberg M, Frankel E. Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathologic studies. Ann Neurol 1983; 14: 316–24

    Article  PubMed  CAS  Google Scholar 

  15. Cunningham D, Morgan RJ, Mills PR, et al. Functional and structural changes of the human proximal small intestine after cytotoxic therapy. J Clin Pathol 1985; 38: 265–70

    Article  PubMed  CAS  Google Scholar 

  16. Allan SG, Smythe JF. Small intestinal mucosal toxicity of cisplatinum: comparison of toxicity with platinum analogues and dexamethasone. Br J Cancer 1986. 53: 355–60

    Article  PubMed  CAS  Google Scholar 

  17. Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother Pharmacol 1981; 7: 11–4

    Article  PubMed  CAS  Google Scholar 

  18. Strum S, McDermed J, Abrahano-Umali R, et al. Management of cisplatin (DDP) induced delayed onset nausea and vomiting: preliminary results with 2 drug regimens. Proc Am Soc Clin Oncol 1985; 4: 263

    Google Scholar 

  19. Clark R, Kris M, Tyson L, et al. Antiemetic trials to control delayed vomiting following high-dose cisplatin [abstract]. Proc Am Soc Clin Oncol 1986; 5: 257

    Google Scholar 

  20. Higgins GA, Kilpatrick GJ, Bunce KT, et al. 5-HT3 receptor antagonists injected into AP inhibit cisplatin induced emesis in ferrets. Br J Pharmacol 1989; 97: 247–55

    Article  PubMed  CAS  Google Scholar 

  21. Sorbe BG, Hogberg T, Glimelius B, et al. A randomized multi-center study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer 1994; 73: 445–54

    Article  PubMed  CAS  Google Scholar 

  22. Hesketh PJ, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis. J Clin Oncol 1996; 14(8): 2242–9

    PubMed  CAS  Google Scholar 

  23. Kris MG, Tyson LB, Clark RA, et al. Oral ondansetron for the control of delayed emesis after cisplatin: report of a phase II study and a review of completed trials to manage delayed emesis. Cancer 1992: 70: 1012–6

    PubMed  CAS  Google Scholar 

  24. Roila F, Bracarda S, Tonato M, et al. Ondansetron (GR 38032) in the prophylaxis of acute and delayed cisplatin-induced emesis. Clin Oncol 1990; 2: 268–72

    Article  CAS  Google Scholar 

  25. DeMulder PHM, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: a multicenter randomized double-blind crossover study. Ann Intern Med 1990; 113: 834–40

    CAS  Google Scholar 

  26. Navari R, Madajewicz S, Anderson N, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large multi-center, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13(9): 2408–16

    PubMed  CAS  Google Scholar 

  27. Johnston D, Latreille J, Laberge F, et al. Preventing nausea and vomiting during days 2–7 following high dose cisplatin chemotherapy. A study by the National Cancer Institute of Canada Clinical Trials Group [abstract]. Proc Am Soc Clin Oncol 1995; 14: 529

    Google Scholar 

  28. Roila F, De Angelis V, Contu A, et al. Ondansetron vs metoclopramide both combined with dexamethasone in the prevention of cisplatin-induced delayed emesis [abstract]. Proc Am Soc Clin Oncol 1996; 15: 528

    Google Scholar 

  29. Schmoll HJ. The role of ondansetron in the treatment of emesis induced by non-cisplatin containing chemotherapy regimens. Eur J Clin Oncol 1989; 25 Suppl. 1: S35–9

    Google Scholar 

  30. Bonneterre J, Chevallier B, Metz R, et al. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990; 8: 1063–9

    PubMed  CAS  Google Scholar 

  31. Kaasa S, Kvaloy S, Dicato MA, et al. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. Eur J Cancer 1990; 26(3): 311–4

    Article  PubMed  CAS  Google Scholar 

  32. Marscher NW, Adler M, Nagel GA, et al. Double-blind randomized trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 1991; 27(9): 1137–40

    Article  Google Scholar 

  33. Soukop M, McQuade B, Hunter E, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 1992; 49: 295–304

    Article  PubMed  CAS  Google Scholar 

  34. Jones AL, Hill AS, Soukop M, et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991; 338: 483–7

    Article  PubMed  CAS  Google Scholar 

  35. Koo WH, Ang PT. Randomized control study to evaluate the role of oral dexamethasone in prevention of chemotherapy-induced delayed emesis [abstract]. Proc Am Soc Clin Oncol 1995; 14: 531

    Google Scholar 

  36. Kaizer L, Warr D, Hoskins P, et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12(5): 1050–7

    PubMed  CAS  Google Scholar 

  37. Perez E. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995; 13(4): 1036–43

    PubMed  CAS  Google Scholar 

  38. Italian Group for Antiemetic Research. Dexamethasone, granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332(1): 1–5

    Article  Google Scholar 

  39. Smith-Kline Beecham Internal Report: MY-1022/BRL 043694/1/CP MS-288, King of Prussia, Pennsylvania, USA

  40. Lofters WS, Zee B. Adding 5-HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy [abstract]. Support Care Cancer 1995; 3: 339

    Google Scholar 

  41. Rittenberg CN, Gralla RJ, Lettow LA, et al. New approaches in preventing delayed emesis: altering the time of regimen initiation and use of combination therapy in a 109 patient trial. Proc Am Soc Clin Oncol 1995; 14: 526

    Google Scholar 

  42. Nakanishi S. Mammalian tachykinin receptors. Annu Rev Neurosci 1991; 14: 123–36

    Article  PubMed  CAS  Google Scholar 

  43. Bountra C, Bunce K, Dale T, et al. Antiemetic profile of a non-peptide antagonist of the substance P (NK1) receptor antagonist, CP-99994, in ferrets. Eur J Pharmacol 1993; 3-4

Download references

Author information

Authors and Affiliations

  1. Section of Medical Oncology, St Elizabeth’s Medical Center of Boston, 736 Cambridge Street, Boston, Massachusetts, MA 02135-2997, USA

    Ranjana Tavorath &  Paul Hesketh

Authors
  1. Ranjana Tavorath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Hesketh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tavorath, R., Hesketh, P. Drug Treatment of Chemotherapy-Induced Delayed Emesis. Drugs 52, 639–648 (1996). https://doi.org/10.2165/00003495-199652050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199652050-00002

Keywords

Search

Navigation